Live Breaking News & Updates on Mediterranea theranostic

Stay updated with breaking news from Mediterranea theranostic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

LegoChem CEO expects $1.72b deal to give traction to ADC development

LegoChem Biosciences will leverage its $1.72 billion out-licensing deal with Janssen Pharmaceuticals for the development of its subsequent antibody-drug conjugate pipelines, the Korean biopharmaceutical firm's CEO said on Wednesday. On Tuesday, the Kosdaq-listed LegoChem signed a technology transfer agreement with Janssen Pharmaceuticals for the development and commercialization of antibody-drug conjugate candid...

Italy , Boston , Massachusetts , United-states , South-korea , Italian , Korea , South-korean , Legochem-biosciences , Mediterranea-theranostic , Janssen-pharmaceuticals , Drug-administration

J&J's Janssen signs licensing deal worth up to $1.7B with LegoChem (NYSE:JNJ)

J&J's Janssen signs licensing deal worth up to $1.7B with LegoChem (NYSE:JNJ)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

South-korea , Legochem-bioscience , Mediterranea-theranostic , Silicon-valley , Janssen-biotech ,

LegoChem CEO expects $1.72b deal to give traction to ADC development

LegoChem Biosciences will leverage its $1.72 billion out-licensing deal with Janssen Pharmaceuticals for the development of its subsequent antibody-drug conjugate pipelines, the Korean biopharmaceutical firm's CEO said on Wednesday. On Tuesday, the Kosdaq-listed LegoChem signed a technology transfer agreement with Janssen Pharmaceuticals for the development and commercialization of antibody-drug conjugate candid...

Italy , South-korea , Boston , Massachusetts , United-states , Italian , South-korean , Korea , Mediterranea-theranostic , Legochem-biosciences , Janssen-pharmaceuticals , Drug-administration

LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

DAEJEON, South Korea, December 26, 2023--LegoChem Biosciences Announces License Agreement for LCB84, a Trop2 directed ADC with Janssen Biotech, Inc., a Johnson & Johnson company.

Daejeon , Taejon-gwangyoksi , South-korea , Mediterranea-theranostic , Yongzu-kim , Legochem-biosciences , Johnson , Janssen-biotech-inc , Legochem-biosciences-inc , Janssen-biotech , Yong-zu-kim , Chem-biosciences

CORRECTING and REPLACING LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC

CORRECTING and REPLACING LegoChem Biosciences Announces License Agreement for LCB84 Trop2-Targeted ADC
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Daeyoung-jeong , Legochem-biosciences , Mediterranea-theranostic , Janssen-biotech-inc , Legochem-biosciences-inc , Johnson , Chem-biosciences , Janssen-biotech , Yong-zu-kim ,